<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537286</url>
  </required_header>
  <id_info>
    <org_study_id>YOUNGBC-11</org_study_id>
    <nct_id>NCT04537286</nct_id>
  </id_info>
  <brief_title>First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients</brief_title>
  <official_title>A Prospective, Single-arm, Open-Label, Phase II Study of Nab-paclitaxel Plus Cisplatin Plus Carilizumab as First-line Treatment in Patients With Metastatic Triple-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of nab-paclitaxel plus cisplatin plus carilizumab as&#xD;
      first-line treatment in patients with metastatic triple-negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>6 weeks</time_frame>
    <description>Progression free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)</intervention_name>
    <description>Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w</description>
    <arm_group_label>nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patients aged 18-70 years who had&#xD;
&#xD;
          2. Metastatic TNBC. ER, PgR, and HER2 status were determined locally by&#xD;
             immunohistochemistry (IHC) of patient primary or metastatic tumor sections. Metastatic&#xD;
             disease was confirmed by clinical, imaging, histological or cytological measures.&#xD;
&#xD;
          3. Patients were required to receive no previous chemotherapy or targeted therapy for&#xD;
             metastatic triple-negative breast cancer.&#xD;
&#xD;
          4. Patients who had received adjuvant/neoadjuvant therapy were required an interval for&#xD;
             at least 6 months after stop of chemotherapy before the enrollment.&#xD;
&#xD;
          5. At least one measurable lesion according to RECIST 1.1,&#xD;
&#xD;
          6. ECOG performance status ≤ 1&#xD;
&#xD;
          7. Life expectancy of more than 12 weeks&#xD;
&#xD;
          8. Adequate organ and bone marrow function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient of childbearing potential but unwilling to receive contraception.&#xD;
&#xD;
          2. Radiation therapy of axial bone within 4 weeks before enrollment.&#xD;
&#xD;
          3. Previous treatment with PD-1 antibody, PD-L1 antibody and CTLA-4 antibody.&#xD;
&#xD;
          4. Patients have active autoimmune diseases.&#xD;
&#xD;
          5. Patients who need systemic corticosteroids (&gt; 10 mg prednisone/d) or other&#xD;
             immunosuppressive drugs within 14 days before enrollment or during the study period.&#xD;
&#xD;
          6. Symptomatic central nervous system (CNS) disease (patients with asymptomatic treated&#xD;
             CNS metastases were permitted)&#xD;
&#xD;
          7. Other malignant diseases within the past 5 years (patients with basal cell skin&#xD;
             carcinoma and cervical carcinoma in situ were permitted)&#xD;
&#xD;
          8. Uncontrolled infection.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biyun Wang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Biyun Wang, Professor</last_name>
    <phone>+8613701748410</phone>
    <email>pro_wangbiyun@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biyun Wang, Professor</last_name>
      <phone>+8613701748410</phone>
      <email>pro_wangbiyun@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 29, 2020</study_first_submitted>
  <study_first_submitted_qc>August 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Biyun Wang, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Shared patient information is not allowed by study center.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

